F. Krammer

Dissecting human monoclonal antibody responses from mRNA- and protein-based XBB.1.5 COVID-19 monovalent vaccines

This study evaluates monoclonal antibody responses to XBB.1.5 vaccines by analyzing plasmablasts from vaccinated individuals and characterizing their binding and neutralization properties against SARS-CoV-2 variants.

Detection of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in New York City

The paper detects H5N1 clade 2.3.4.4b influenza viruses in urban birds in New York City and highlights the urban animal-human interface as a potential zoonotic risk.

Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated

This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.

Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

This study identifies non-neutralizing antibodies from vaccinated individuals that protect against SARS-CoV-2 in animal models, highlighting their role through Fc-mediated effector functions and conserved epitope binding.

Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participants

This study identifies immune programs linked to COVID-19 severity and mortality through longitudinal multi-omics analysis of 1,152 hospitalized patients.

Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection

This study compares mucosal antibody responses in individuals who received mRNA booster vaccinations or experienced breakthrough infections, finding that breakthrough infections induce stronger saliva sIgA responses than boosters.

Prolonging the Delivery of Influenza Virus Vaccine Improves the Quantity and Quality of the Induced Immune Responses in Mice

This study shows that prolonged influenza vaccine delivery in mice enhances both the quantity and quality of immune responses compared to prime-boost immunization.

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants

This paper identifies a broadly neutralizing antibody against SARS-CoV-2 that targets the receptor-binding site and remains effective against multiple Omicron subvariants.

Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination

This study investigates whether immunity to seasonal coronavirus spike proteins protects against SARS-CoV-2 in mice and affects mRNA vaccine efficacy, finding no increased protection but no detrimental effect on vaccination.

Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner

This study shows that an intranasal recombinant influenza B virus neuraminidase vaccine can block viral transmission in guinea pigs depending on exposure intensity.

Antigenic landscape analysis of individuals vaccinated with a universal influenza virus vaccine candidate reveals induction of cross-subtype immunity

The paper analyzes immune responses to a universal influenza vaccine using a microarray to show broad antibody coverage against group 1 hemagglutinins.

Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins

This paper reports the development of two DARPins, FSR16m and FSR22, that potently neutralize SARS-CoV-2 variants, including emerging ones, with efficacy comparable to therapeutic antibodies.

Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice

The paper tests a trivalent NDV-HXP-S vaccine against SARS-CoV-2 variants in mice, showing increased protection and cross-neutralizing antibodies against Omicron.

Mapping SARS-CoV-2 antigenic relationships and serological responses

The paper uses antigenic cartography to analyze cross-reactivity among SARS-CoV-2 variants and human sera, identifying amino acid substitutions and immunodominance patterns affecting immune escape and vaccine efficacy.

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

Maternal cytokine response after SARS-CoV-2 infection during pregnancy

This study examines if SARS-CoV-2 infection during pregnancy leads to lasting changes in maternal cytokine levels, finding no significant differences between infected and uninfected groups.

Detection of velogenic avian paramyxoviruses in rock doves in New York City, New York

The paper screens wild birds in NYC for APMV-1, identifies two isolates, and classifies them into genotype VI, highlighting their potential role in NDV outbreaks.

Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles

This study compares the Fc-functional antibody profiles of mRNA-1273 and BNT162b2 vaccines in a cohort of hospital staff, finding differences in epitope-specific responses and effector functions.

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2

This study evaluates cross-neutralizing antibody responses and protective efficacy of vaccines based on SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 in mice against wild type SARS-CoV-2 challenge.

Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD

The paper structures a germline-like antibody in complex with SARS-CoV-2 spike NTD, revealing a neutralizing epitope and its conservation across variants.

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

This study develops a Newcastle disease virus-based vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein, showing strong immune responses and cross-neutralization against variants in mice and hamsters.

Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner

This study evaluates murine monoclonal antibodies against SARS-CoV-2 RBD, showing neutralization of wild-type and variants, and in vivo protection dependent on neutralization.

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

Novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase

This study identifies novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase and characterizes escape mutations and their impact on viral fitness.

A public broadly neutralizing antibody class targets a membrane-proximal anchor epitope of influenza virus hemagglutinin

This study identifies a class of broadly neutralizing antibodies targeting a conserved membrane-proximal epitope on influenza HA, showing their induction by a chimeric HA vaccine.

Monoclonal antibodies targeting the influenza virus N6 neuraminidase

This study generates and characterizes monoclonal antibodies against the N6 neuraminidase subtype of influenza viruses, showing broad reactivity and antiviral activity, but limited inhibition of H5N6 NA.

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques

This study shows intranasal ChAdOx1 nCoV-19 vaccination reduces SARS-CoV-2 shedding in animal models but not pneumonia protection.

Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus

The paper functionally and antigenically characterizes the hemagglutinin and neuraminidase of Wuhan spiny eel influenza virus to assess its status as a bona fide influenza virus.